VIARTIS

 

 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

10th November 2012 - News release

A FUTURE REPLACEMENT FOR SINEMET

Depomed are developing a new drug called DM-1992 that could outperform Sinemet in the treatment of Parkinson's Disease. Just like Sinemet, DM-1992 is a combination of L-dopa and carbidopa, which prevents the breakdown of L-dopa.  DM-1992 also includes AcuForm, which makes use of the properties of certain polymers. These polymers have long been used to "fluff" ice cream and are safe to use. Upon entering the stomach an AcuForm coated pill expands and is retained in the stomach for up to 8 hours. For more information go to Depomed.

AcuForm helps to deliver a drug like Sinemet over a longer period of time. Depomed's formulation was able to extend the therapeutic duration of L-dopa to nine hours, compared to Sinemet CR's seven hours. The time to reach peak blood levels was extended to four hours compared to 2 hours for Sinemet CR. These advantages could enable a decrease in the dosage of L-dopa, and the ridding of side effects such as nausea and dyskinesia. In the most recent clinical trial, DM-1992 reduced off time from 5.4 hours per day to 4.5 hours per day. DM-1992 was generally well tolerated in the study, and there were no serious adverse events. For the news release click here. For a printable version of this article click here. For more news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports

                                    

 

 
©2006-2012  Viartis
 
2015-08-29 19:36:21
 
[email protected]